Kwality Pharmaceuticals cuts cash conversion cycle to 130 days

Kwality Pharmaceuticals reduced its cash conversion cycle to 130 days in H1FY27, 40 days below FY26's 170 days and 167 days below FY23's 297 days. Inventory days fell 34 days to 77 and debtor days declined 25 days to 178, while trade receivables nevertheless rose to Rs 335 crore.

How did Kwality reduce its cash conversion cycle to 130 days?

Kwality reduced its cash conversion cycle, the period between supplier payments and customer collections, to 130 days in H1FY27. This compares with 170 days in FY26, 208 days in FY25, 217 days in FY24 and 297 days in FY23, a 167-day reduction across the periods presented.

The H1FY27 movement involved all three components of working capital. Debtor days declined to 178 from 203 in FY26, inventory days declined to 77 from 111, and payable days declined to 126 from 144. Lower payable days mean Kwality took fewer days to pay suppliers, which reduced part of the cash benefit generated by lower inventory and debtor days.

Why did inventory days matter most to Kwality's improvement?

Inventory days made the largest contribution to the six-month reduction, falling 34 days to 77 in H1FY27 from 111 in FY26. The ratio declined in every reported period since FY23, moving from 310 days in FY23 to 187 in FY24, 167 in FY25, 111 in FY26 and 77 in H1FY27.

Inventories were Rs 74 crore in H1FY27, down from Rs 78 crore in FY26, while revenue from operations reached Rs 181.2 crore in Q2FY27, compared with Rs 162.4 crore in Q1FY27. Cost of goods sold was Rs 86.7 crore in Q2FY27, marginally below Rs 87.4 crore in Q1FY27, while gross profit increased 26% quarter on quarter to Rs 94.5 crore.

Kwality attributes the working-capital trend to tighter inventory and receivables discipline while the business scales. The inventory balance declined by Rs 4 crore from FY26 as Q2FY27 revenue was 62% above Rs 111 crore in Q2FY26. The presentation does not disclose inventory turns, product-level stock data or operating cash flow that would quantify cash released from inventory management.

Have Kwality's receivables improved despite a higher balance?

Kwality's debtor days improved to 178 in H1FY27 from 203 in FY26, but trade receivables increased to Rs 335 crore from Rs 280 crore. The days ratio indicates a quicker collection relationship to sales, whereas the balance-sheet figure shows a larger amount remained outstanding from customers at the interim date.

Trade receivables rose in each period shown, from Rs 72 crore in FY23 to Rs 115 crore in FY24, Rs 154 crore in FY25, Rs 280 crore in FY26 and Rs 335 crore in H1FY27. Over the same periods, debtor days increased from 104 in FY23 to 136 in FY24, 152 in FY25 and 203 in FY26, before the 25-day reduction in H1FY27.

Receivables exceeded inventories by Rs 261 crore in H1FY27, compared with a Rs 202 crore gap in FY26. The 25-day debtor-days improvement therefore occurred alongside a Rs 55 crore increase in receivables; Q2FY27 revenue was Rs 181.2 crore. Kwality does not provide customer concentration, receivables ageing, payment terms or overdue-balance data in the presentation.

How did Kwality's liabilities and cash balances change?

Kwality's trade payables rose to Rs 120 crore in H1FY27 from Rs 102 crore in FY26, while payable days declined to 126 from 144. The increase in the absolute payable balance alongside fewer payable days shows that the balance-sheet amount and the operating ratio moved in different directions over the six-month period.

Current borrowings increased to Rs 108 crore in H1FY27 from Rs 101 crore in FY26, and non-current borrowings increased to Rs 38 crore from Rs 29 crore. Cash and bank balances were Rs 2 crore at H1FY27, compared with Rs 1 crore in FY26, while other bank balances were unchanged at Rs 3 crore.

Current assets reached Rs 481 crore in H1FY27 from Rs 406 crore in FY26, including the Rs 55 crore increase in trade receivables and a Rs 19 crore increase in other current assets to Rs 54 crore. Current liabilities included Rs 120 crore of trade payables, Rs 108 crore of borrowings and Rs 16 crore of other current liabilities; the presentation does not report a current ratio or operating cash-flow figure.

How does working-capital progress align with Kwality's growth plan?

Kwality reported revenue from operations of Rs 181.2 crore in Q2FY27, up 12% from Rs 162.4 crore in Q1FY27 and 62% from Rs 111 crore in Q2FY26. Earnings before interest, tax, depreciation and amortisation, or EBITDA, were Rs 49.8 crore, up 21% quarter on quarter, and EBITDA margin was 27.5%, compared with 25.3% in Q1FY27.

Management raised FY27 revenue guidance to Rs 720 crore or more from Rs 700 crore or more previously, compared with FY26 revenue of Rs 503 crore. It retained EBITDA guidance of Rs 189 crore to Rs 196 crore or a margin of 27% to 28% or more, and raised profit after tax guidance to Rs 122 crore or more from Rs 109 crore previously.

The development programme includes 40 products, comprising 11 oncology, 27 general and two beta lactam products. Kwality reported 19 dossiers available for global filing, with seven dossiers planned by Q4 2026 and 14 by Q1 2027; it also disclosed oncology-capacity expansion targeted for June 2027.

Conclusion

Kwality's H1FY27 disclosure shows a shorter 130-day cash conversion cycle, led by the 34-day reduction in inventory days and supported by a 25-day reduction in debtor days. Trade receivables, however, increased to Rs 335 crore, meaning the improved efficiency ratio did not coincide with a lower absolute amount tied up in customer balances.

The next measures to watch are debtor days and receivables growth as management pursues FY27 revenue of Rs 720 crore or more. The presentation also sets dossier milestones of seven by Q4 2026 and 14 by Q1 2027, while oncology-capacity expansion is targeted for June 2027.